Portal de Periódicos da CAPES

TP or Not TP: Primary Mediators in a Close Runoff?

2000; Lippincott Williams & Wilkins; Volume: 20; Issue: 7 Linguagem: Inglês

10.1161/01.atv.20.7.1695

1524-4636

Domenico Praticò, Yan Cheng, Garret A. FitzGerald,

Venous Thromboembolism Diagnosis and Management

HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 20, No. 7TP or Not TP: Primary Mediators in a Close Runoff? Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBTP or Not TP: Primary Mediators in a Close Runoff? Domenico Praticó, Yan Cheng and Garret A. FitzGerald Domenico PraticóDomenico Praticó From the Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia. , Yan ChengYan Cheng From the Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia. and Garret A. FitzGeraldGarret A. FitzGerald From the Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia. Originally published1 Jul 2000https://doi.org/10.1161/01.ATV.20.7.1695Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1695–1698Aspirin has emerged as a remarkably safe, inexpensive, and effective drug for the secondary prevention of the complications of atherosclerotic disease. It acts by inhibiting the enzyme prostaglandin (PG) G/H synthase, actually a bifunctional protein that sequentially catalyzes the conversion of arachidonic acid to the highly reactive endoperoxide intermediates PGG2 and PGH2 via its cyclooxygenase (COX) and peroxidase functions. This enzyme, colloquially termed COX, has been crystallized1 and the mechanism of action of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) elucidated.234 The catalytic site is buried deep within the core of the enzyme and is accessed by the substrate via a hydrophobic tunnel. Aspirin irreversibly acetylates a serine residue at position 529 in the human enzyme,5 close to but not at the catalytic site, though still blocking access to it by the arachidonic acid substrate. NSAIDs, by contrast, act reversibly as competitive inhibitors at the catalytic site. Indeed, transient occupancy of that site after dosing with an NSAID may mask the serine from the effects of a subsequent dose of aspirin.6The beneficial effects of aspirin in cardiovascular disease have been attributed to its inhibitory effects on COX in platelets. In these cells, thromboxane (Tx) synthase further catalyzes the conversion of PGH2 to TxA2,7 which exerts proaggregatory, vasoconstrictor, and proliferative effects via a membrane-bound, G protein–coupled receptor, the TP.8 Two isoforms (α and β) of the TP have been cloned,89 both of which are transcribed in human platelets, although only TPα appears to be translated.10 Transcripts of both isoforms are present in vascular cells.11 Although the isoforms differ in their rates of agonist-induced desensitization12 and propensity to couple with G proteins,13 little is known of their disparate roles in vivo. The importance of TxA2 in platelet activation is thought to derive principally from its role as an amplifying signal for other stronger, primary agonists, such as thrombin and ADP.14 However, the clinical efficacy of aspirin complements that of ticlopidine,15 a drug that selectively inhibits platelet aggregation induced by ADP but not TP agonists ex vivo. Clopidogrel, a close relative of ticlopidine, appears to act by a similar mechanism.15 In a large-scale clinical trial, clopidogrel emerged as slightly more efficacious than aspirin in the secondary prevention of myocardial infarction and stroke.16The irreversible acetylation of Ser529 by aspirin in the COX of anucleate platelets explains the cumulative inhibition of the capacity of platelets to generate TxA2, commonly measured as serum concentrations of its hydrolysis product TxB2. Thus, daily administration of 75 mg of aspirin takes 3 to 4 days to inhibit completely serum TxB2 ex vivo.17 Interestingly, like low-dose aspirin, 75 mg of clopidogrel also takes several days to inhibit platelet function ex vivo, perhaps owing to the gradual accumulation of a metabolite that binds to a subclass of purinergic receptors, although this has yet to be established in vivo. As in the case of aspirin, loading doses of clopidogrel have been investigated and are likely to be employed in acute settings of vascular occlusion. Studies designed to assess the potentially additive effects of aspirin with clopidogrel have been initiated. Finally, dipyridamole has been reformulated to correct prior problems with variable and transient bioavailability. This new preparation has been shown to be as effective as low-dose aspirin in the secondary prevention of stroke, and the benefit from a combination of the 2 is roughly additive.18 This has led to the US Federal Drug Administration approval of an aspirin-dipyridamole combination for this indication. Although oral inhibitors of the platelet glycoprotein αIIb/βIII have been disappointing, 3 antiplatelet drugs—low-dose aspirin, clopidogrel, and dipyridamole—have been proven effective in the secondary prevention of cerebrovascular and/or cardiovascular disease. Their mechanisms of action suggest that their benefits might be additive, although this remains to be established in a clinical trial. This has "raised the bar" for the development of potentially novel therapies in this arena.The advent of pharmacological inhibitors of the TP192021 inauspiciously coincided with the initial trials establishing the efficacy of aspirin in cardiovascular disease.222324 This confounded their development in 2 ways. First, as the effects of aspirin were attributed to inhibition of TxA2, TP antagonists had little additional benefit to offer. Perhaps preservation of the ability of the vasculature to generate other PGs such as prostacyclin (PGI2) was a plus, but this was a strictly theoretical concept. Against that, it was difficult for TP antagonists to compete against aspirin at 20 cents a tablet. Two clinical trials of TP antagonists were performed, both addressing the possibility that they might modify restenosis after angioplasty.In the CARPORT (Coronary Artery Restenosis Prevention on Repeated Thromboxane A2 antagonism) study, the antagonist GR32191, given before percutaneous transluminal coronary angioplasty (PTCA) and for 6 months thereafter, did not differ significantly from the effects of intravenous aspirin given immediately before PTCA on luminal diameter as assessed by angiography performed 6 months after the intervention.25 However, the limitations of this uncontrolled experience and of relying on an angiographic end point at a single time were highlighted by the M-HEART (Multi-Hospital Eastern Atlantic Restenosis Trial) II study.26 In that study, all patients received aspirin before PTCA due to its role, by then established, in the prevention of periprocedural myocardial infarction27 but were randomized to continuing treatment with the TP antagonist sulotroban, aspirin, or placebo. In this case, the angiographic estimate of vascular occlusion at 6 months was a secondary end point and did not differ between the groups. By contrast, continued treatment with either aspirin or sulotroban significantly reduced the later myocardial infarction rate in the 6 months after PTCA when compared with the placebo group. These observations left many unanswered questions. First, aside from there being no measure of the degree of synthesis inhibition achieved by aspirin or of TP blockade by either antagonist, the divergence of the time-integrated clinical and "snapshot" angiographic end points in the M-HEART II study illustrated the limited information available from CARPORT. Second, the hypothesis that TP blockade might be superior to aspirin was configured on the preservation of PGI2 formation during TP blockade. PGI2 has significant antiproliferative effects. Both virally delivered PGI synthase and a PGI2 analogue, beraprost, have been shown to reduce significantly the proliferative response to experimental angioplasty.2829 However, the procedure-related increase in PGI2 biosynthesis, like that in TxA2, is short-lived and suppressed by aspirin in patients undergoing PTCA,3031 and the patients assigned to sulotroban were receiving aspirin at that time.Cayette and colleagues32 now report observations that suggest that reconsideration of the role of TP antagonism is timely. Using a newly synthesized TP antagonist, S18886, which is devoid of partial agonist activity, they report that atherogenesis can be retarded in the apoE-knockout (KO) mouse. Oddly, aspirin has no effect. One possibility is that inhibition of other COX products by aspirin, such as PGI2, might have obscured a benefit from inhibiting TxA2. We now know that deletion of the PGI2 receptor—the IP—results in an increased response to thrombotic stimuli in vivo,8 but the role of this mediator in atherogenesis is unknown. We also now know that there are 2 forms of COX.4 The second isoform is a distinct gene product and is readily regulated in its expression by growth factors, tumor promoters, and cytokines. The tertiary structures of the 2 enzymes are remarkably similar4 ; however, the hydrophobic channel of COX-2 is more accommodating. Both COX isozymes form small amounts of 11(S)- and 15(S)-hydroxyeicosatetraenoic acids (HETEs). It is unknown whether they contribute to COX actions in vivo, although some HETEs have been shown to be weak TP agonists in vitro. 15(S)-HETE can also be formed as a primary product by the 15-lipoxygenase enzyme. Deletion of this enzyme reverses atherogenesis in the apoE-KO mouse.33 Interestingly, unlike the case with COX-1, inhibition of COX-2–dependent PG synthesis by aspirin, but not by NSAIDs, ex vivo or in vitro is accompanied by increased generation of both 11- and 15-HETEs, but now in the R stereoconfiguration. The acetyl residue is thought to force realignment of the ω end of the arachidonic acid carbon chain, which is usually oriented in an L-shaped configuration in the hydrophobic channel.34 Mutation to their COX-1 equivalents of 3 residues predicted to be critical to the spatial and flexibility differences in the COX-2 channel abolishes this feature in the mouse enzyme.35 Both COX isoforms are present, with remarkably similar distributions, in human atherosclerotic plaque.36 Although this may also be true in the atherosclerotic mouse, it is unknown whether 15(R)-HETE has any biological effects in aspirin-treated animals. Thus for now, the role of TP activation by HETEs in explaining the discrepancy between the effects of aspirin and the TP antagonist in the study of Cayette and colleagues32 remains quite speculative. Perhaps the explanation is more mundane. The relationship between inhibition of the capacity of platelets to generate TxA2—estimated by serum TxB2—and inhibition of Tx-dependent platelet activation is remarkably nonlinear. Just 5% residual capacity is sufficient fully to sustain function.37 In the present study, the aspirin regimen suppressed serum TxB2 by only 70% to 75%, and TP-dependent platelet activation is likely to have been unimpaired. Clearly, platelets may be a source of growth factors relevant to atherogenesis, but activation of TPs in other cells may also be relevant. In tissues other than the platelet, we have no information as to the relationship between biosynthetic capacity and function.Cayette and colleagues32 raise the possibility that the discrepant results between aspirin and S 18886 might also be explained if isoprostanes (iPs), free radical–catalyzed products of arachidonic acid, played an important role in TP activation. Indeed, at least 2 iPs—iPF2α-III (also known as 8-iso-PGF2α38 ) and iPE2-III—exert potent effects on platelet function and vascular tone, and these actions are prevented by TP antagonists and absent in TP-deficient mice.39 Generation of iPs is increased in both humans with atherosclerosis40 and in apoE-KO mice, and iP suppression with vitamin E retards atherogenesis in this model.41 Perhaps the use of TP antagonists should be reconsidered in other syndromes in which oxidant stress and COX activation coincide, such as occlusion/reperfusion and inflammation. We are at a very early stage in elucidating the biological actions of iPs and related compounds, some of which may act as incidental ligands at other PG receptors.42Where do the observations of Cayette and colleagues32 lead us? It would certainly be interesting to confirm the effects of the compound in murine models more reminiscent of the human disease.43 It would also be reassuring to confirm that similar effects are observed with structurally distinct antagonists and TP deletion. It remains a formal possibility that the observed effects relate to properties of S 18886 that are unrelated to TP antagonism. Such studies will also increase our sense of the magnitude of the effect we might anticipate with TP antagonism. This seems consistent, but somewhat modest, in the apoE-KO mouse. Should such studies reinforce our confidence, modern imaging modalities such as electron beam CT of the coronary44 or ultrasonography of the carotid arteries45 afford noninvasive approaches to assess the impact of TP antagonism on plaque progression in humans. Reagents are now available for the study of TP expression in human disease,46 and model systems have implicated TP activation in settings previously not considered when these drugs were under development.47 Finally, TP antagonists may even be worth considering as alternative platelet inhibitors to aspirin in certain circumstances. For example, because platelets express COX-1 only, selective inhibitors of COX-2 do not afford cardioprotection. However, in the absence of any actual clinical data, the empiric combination of these drugs with low-dose aspirin has some theoretical limitations. Even low-dose aspirin causes gastrointestinal side effects,48 which may erode the postulated benefit of selective COX-2 inhibition on the gastrointestinal tract. By contrast, TP antagonism has been shown to protect against NSAID-induced enteropathy in the rat.49 Similarly, selective COX-2 inhibitors, NSAIDs, and even low doses of conventionally formulated aspirin depress PGI2 biosynthesis in healthy individuals.5051 Combination of TP antagonists with COX-2 inhibitors would afford at least similar cardioprotection to that of aspirin25 while sparing PGI2 formation from further suppression.In summary, the provocative studies of Cayette et al32 draw attention to a class of compounds that were previously abandoned for reasons that were rational at the time. Now that we know more about the breadth of potential TP ligands and are increasingly informed of the biology of PGs as a result of the availability of receptor-deficient mice, it would seem worthwhile to reconsider the contemporary utility of this interesting class of compounds.FootnotesCorrespondence to Dr G.A. FitzGerald, Center for Experimental Therapeutics, 153 Johnson Pavillion, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. E-mail [email protected]@spirit.gcrc.upenn.edu References 1 Picot D, Loll PJ, Garavito M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature.1994; 367:243–249.CrossrefMedlineGoogle Scholar2 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets, I: acetylation of a particulate fraction protein. J Clin Invest.1975; 56:624–632.CrossrefMedlineGoogle Scholar3 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med.1994; 330:1287–1294.CrossrefMedlineGoogle Scholar4 Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem.1996; 271:33157–33160.CrossrefMedlineGoogle Scholar5 Funk CD, Funk LB, Kennedy M, Pong A, FitzGerald GA. Human platelet/erythroleukemia cell PGG/H synthase: cDNA cloning, expression, mutagenesis and gene chromosomal assignment. FASEB J.1991; 5:2304–2312.CrossrefMedlineGoogle Scholar6 Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol.1995; 2:637–643.CrossrefMedlineGoogle Scholar7 Hamberg M, Svensson J, Samueilsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A.1975; 72:2994–2998.CrossrefMedlineGoogle Scholar8 Hirata M, Hayashi Y, Ushikubi F, et al. Cloning and expression of cDNA for human thromboxane A2 receptor. Nature..1991; 349:617–620.CrossrefMedlineGoogle Scholar9 Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem.1994; 269:19256–19261.CrossrefMedlineGoogle Scholar10 Habib A, FitzGerald GA, Maclouf J. Phosphorylation of the thromboxane receptor, the predominant isoform expressed in human platelets. J Biol Chem.1999; 274:2645–2654.CrossrefMedlineGoogle Scholar11 Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) α and β isoforms. Biochim Biophys Acta.1998; 1425:543–559.CrossrefMedlineGoogle Scholar12 Parent JL, Labrecque P, Orsini MJ, Benovic JL. Internalization of the TxA2 receptor α and β isoforms: role of the differentially spliced COOH terminus in agonist-promoted receptor internalization. J Biol Chem.1999; 274:8941–8948.CrossrefMedlineGoogle Scholar13 Vezza R, Habib A, FitzGerald GA. Differential coupling of the thromboxane receptor isoforms with Gh. J Biol Chem.1999; 274:12774–12779.CrossrefMedlineGoogle Scholar14 FitzGerald GA. Mechanisms of platelet activation: TxA2 as an amplifying signal for other agonists. Am J Cardiol.1991; 68:11B–15B.CrossrefMedlineGoogle Scholar15 Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation.1999; 100:1667–1672.CrossrefMedlineGoogle Scholar16 CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet.1996; 348:1329–1339.CrossrefMedlineGoogle Scholar17 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest.1982; 69:1366–1372.CrossrefMedlineGoogle Scholar18 Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, II: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci.1996; 143:1–13.CrossrefMedlineGoogle Scholar19 Gresele P, Arnout J, Janssens W, Deckmyn H, Lemmens J, Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet.1984; 1:991–994.MedlineGoogle Scholar20 Darius H, Smith JB, Lefer AM. Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29, 548) in vitro and in vivo. J Pharmacol Exp Ther.1985; 235:274–281.Google Scholar21 Humphrey PPA, Hallet P, Hornby EJ, Wallis CJ, Collington EW, Lumley P. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191. Circulation. 1990;81(suppl I):I-42–I-52.Google Scholar22 Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3d. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med.1983; 309:396–403.CrossrefMedlineGoogle Scholar23 ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet.1988; 2:349–360.MedlineGoogle Scholar24 Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med.1985; 313:1369–1375.CrossrefMedlineGoogle Scholar25 Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stribbe J. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2 receptor blockade: a randomized, double-blind, placebo-controlled trial. Circulation.1991; 84:1568–1580.CrossrefMedlineGoogle Scholar26 Savage MP, Goldberg S, Bove AA, Deutsch E, Vetrovec G, Macdonald RG, Bass T, Margolis JR, Whitworth HB, Taussig A. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-Heart II). Circulation.1995; 92:3194–3200.CrossrefMedlineGoogle Scholar27 Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med.1988; 318:1714–1719.CrossrefMedlineGoogle Scholar28 Todaka T, Yokoyama C, Yanamoto H, Hashimoto N, Nagata I, Tsukahara T, Hara S, Hatae T, Morishita R, Aoki M, Ogihara T, Kaneda Y, Tanabe T. Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. Stroke.1999; 30:419–426.CrossrefMedlineGoogle Scholar29 Isogaya M, Yamada N, Koike H, Ueno Y, Kumagai H, Ochi Y, Okazaki S, Nishio S. Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty. J Cardiovasc Pharmacol.1995; 25:947–952.CrossrefMedlineGoogle Scholar30 Roy L, Knapp H, Robertson RM, FitzGerald GA. Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. Circulation.1985; 71:434–449.CrossrefMedlineGoogle Scholar31 Braden G, Knapp HR, FitzGerald GA. Suppression of eicosanoid formation during coronary angioplasty by fish oil and aspirin. Circulation.1991; 84:679–685.CrossrefMedlineGoogle Scholar32 Cayatte AJ, Du Y, Oliver-Krasinki J, et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E–deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol.2000; 20:1724–1728.CrossrefMedlineGoogle Scholar33 Cyrus, T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MRF, Funk CD. J Clin Invest. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest.1999; 103:1597–1604.CrossrefMedlineGoogle Scholar34 Schneider C, Brash AR. Stereospecificity of hydrogen abstraction in the conversion of arachidonic acid to 15R-HETE by aspirin-treated cyclooxygenase-2. J Biol Chem.2000; 275:4743–4746.CrossrefMedlineGoogle Scholar35 Rowlinson SW, Crews BC, Goodwin DC, Schneider C, Gierse JK, Marnett LJ. Spatial requirements for 15-(R)-hydroxy-5z, 8z, 11z, 13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. J Biol Chem.2000; 275:6586–6591.CrossrefMedlineGoogle Scholar36 Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol.1999; 155:1281–1291.CrossrefMedlineGoogle Scholar37 Reilly IAG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood.1987; 69:180–186.CrossrefMedlineGoogle Scholar38 Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo [Mini-review]. J Biol Chem.1999; 274:24441–24444.CrossrefMedlineGoogle Scholar39 Audoly LP, Rocca B, Fabre J-E, Koller BH, Thomas D, Loeb A, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes, iPF2α-III and iPEα-III are mediated via the thromboxane A2 receptor in vivo. Circulation. In press.Google Scholar40 Reilly M, Praticò D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation.1998; 98:2822–2828.CrossrefMedlineGoogle Scholar41 Praticò D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med.1998; 4:1189–1192.CrossrefMedlineGoogle Scholar42 Kunapuli P, Lawson JA, Rokach JA, Meinkoth JL, FitzGerald GA. Prostaglandin F2α (PGF2α) and the isoprostane, 8-,12-iso-isoprostane F2α-III, induce cardiomyocyte hypertrophy: differential activation of downstream signaling pathways. J Biol Chem.1998; 273:22442–22452.CrossrefMedlineGoogle Scholar43 Rader D, FitzGerald GA. State of the art: arthrosclerosis in a limited edition [News and Views]. Nat Med.1998; 4:899–900.CrossrefMedlineGoogle Scholar44 Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol.1990; 15:827–832.CrossrefMedlineGoogle Scholar45 Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb.1994; 14:1098–1104.CrossrefMedlineGoogle Scholar46 Habib A, Vezza R, Creminon C, Maclouf J, FitzGerald GA. Rapid, agonist-dependent phosphorylation of human thromboxane receptors: minimal involvement of protein kinase C. J Biol Chem.1997; 272:7191–7200.CrossrefMedlineGoogle Scholar47 Rocca B, Loeb A, Strauss JA, Vezza R, Li H-W, FitzGerald GA. Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med..2000; 6:219–221.CrossrefMedlineGoogle Scholar48 Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Sixth ACCP Consensus Conference on Antithrombotic Therapy Platelet-Active Drugs: the relationships among dose, effectiveness, and side effects. Chest.Google Scholar49 Ogletree ML, O'Keefe EH, Durham SK, Rubin B, Aberg G. Gastroprotective effects of thromboxane receptor antagonists. J Pharmacol Exp Ther.1992; 263:374–380.MedlineGoogle Scholar50 McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A.1999; 96:272–277.CrossrefMedlineGoogle Scholar51 FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest..1983; 71:676–688.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Davì G, Santilli F and Vazzana N (2012) Thromboxane Receptors Antagonists and/or Synthase Inhibitors Antiplatelet Agents, 10.1007/978-3-642-29423-5_11, (261-286), . Rovati G, Sala A, Capra V, Dahlén S and Folco G (2010) Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk, Trends in Pharmacological Sciences, 10.1016/j.tips.2009.11.007, 31:3, (102-107), Online publication date: 1-Mar-2010. Heeneman S, Donners M, Bai L and Daemen M (2014) Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?, Expert Review of Cardiovascular Therapy, 10.1586/14779072.5.2.345, 5:2, (345-364), Online publication date: 1-Mar-2007. Egan K and FitzGerald G Eicosanoids and the Vascular Endothelium The Vascular Endothelium I, 10.1007/3-540-32967-6_6, (189-211) Cracowski J and Durand T (2006) Cardiovascular pharmacology and physiology of the isoprostanes, Fundamental and Clinical Pharmacology, 10.1111/j.1472-8206.2006.00435.x, 20:5, (417-427), Online publication date: 1-Oct-2006. Cracowski J, Berdeaux O and Durand T (2005) Les isoprostanes, biomarqueurs de peroxydation lipidique chez l'homme. Partie 3 : biomarqueurs et médiateurs en physiologie et pathologie vasculaire, Pathologie Biologie, 10.1016/j.patbio.2004.10.007, 53:6, (364-368), Online publication date: 1-Jul-2005. Maalej N, Osman H, Shanmuganayagam D, Shebuski R and Folts J (2005) Antithrombotic Properties of the Thromboxane A2/Prostaglandin H2 Receptor Antagonist S18886 on Prevention of Platelet-Dependent Cyclic Flow Reductions in Dogs, Journal of Cardiovascular Pharmacology, 10.1097/01.fjc.0000157439.49612.83, 45:5, (389-395), Online publication date: 1-May-2005. Cracowski J (2004) Les isoprostanes : un rôle physiopathologique potentiel en pathologie vasculaire, La Revue de Médecine Interne, 10.1016/j.revmed.2004.02.022, 25:6, (459-463), Online publication date: 1-Jun-2004. Cracowski J (2004) Isoprostanes: an emerging role in vascular physiology and disease?, Chemistry and Physics of Lipids, 10.1016/j.chemphyslip.2003.10.006, 128:1-2, (75-83), Online publication date: 1-Mar-2004. Osende J, Shimbo D, Fuster V, Dubar M and Badimon J (2004) Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7933.2004.00639.x, 2:3, (492-498), Online publication date: 1-Mar-2004. Praticò D, Tillmann C, Zhang Z, Li H and FitzGerald G (2001) Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice, Proceedings of the National Academy of Sciences, 10.1073/pnas.061607398, 98:6, (3358-3363), Online publication date: 13-Mar-2001. July 2000Vol 20, Issue 7 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.20.7.1695 Originally publishedJuly 1, 2000 Keywordsthromboxaneatherosclerosisoxidant stressisoprostaneEditorialsPDF download Advertisement